If PAR aren't yet aware of the FDA feedback, as stated in the quote that you (Mozz) posted, then where has PR plucked "2024" and the additional trial recipient numbers from?
This was the point i was trying to make earlier. PAR will likely already be aware of some of the FDA recommendations even though they are still awaiting the formal written response by the FDA, otherwise what would be the reason for the changes. Were these changes part of the original briefing package sent to the FDA or have they been made more recently. It seems the CEO let the information slip unintentionally potentially as a result of the interviewer's style of interviewing, or at least that's the way I seen it.
Remember DYOR
https://www.fda.gov/media/72253/download
Ann: Paradigm to Present at Evercore ISI HealthCONx Conference, page-172
-
- There are more pages in this discussion • 117 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 387930 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 65468 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |